Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Click Therapeutics has collected a groundbreaking green light from the FDA for the agency’s first prescription digital ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from dangerous allergic reactions.

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...